The GORE® TAG® Conformable Thoracic Stent Graft with ACTIVE CONTROL System was launched in the USA at the 2019 SVS Vascular Annual Meeting (VAM; 12–15 June 2019, National Harbor), just weeks after the device obtained FDA approval.
Dittmar Böckler (Heidelberg, Germany), distils two years of European experience with the “highly conformable” device. “One of the biggest achievements is the staged deployment for more accurate deployment, a new deployment sequence that makes it suitable not just for the arch, but also challenging distal anatomies. Optional angulation allows the operator to optimise conformability and enhance apposition,” he says.
Böckler tells Vascular News that access to the new device has “dramatically changed” his daily practice and that the team has now increased the number of patients undergoing percutaneous access due to the reduced profile of the stent graft and that they have abandoned rapid pacing as a standard practice with this device.
This video was sponsored by W.L. Gore & Associates.
